A rate equation approach to elucidate the kinetics and robustness of the TGF-beta pathway

Melke, Pontus; Jönsson, Henrik; Pardali, Evangelia; ten Dijke, Peter; Peterson, Carsten

Published in:
Biophysical Journal

DOI:
10.1529/biophysj.105.080408

2006

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain.
• You may freely distribute the URL identifying the publication in the public portal.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
This is an author produced version of a paper published in Biophysical Journal

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:

P. Melke, H. Jönsson, E. Pardali, P. ten Dijke, and C. Peterson
A rate equation approach to elucidate the kinetics and robustness of the TGF-β pathway

http://dx.doi.org/10.1007/s00344-006-0066-x

Access to the published version may require subscription.
Published with permission from: Biophysical Society
A rate equation approach to elucidate the kinetics and robustness of the TGF-β pathway

Pontus Melke¹,
Henrik Jönsson¹
Computational Biology & Biological Physics
Lund University, Lund, Sweden

Evangelia Pardali,
Peter ten Dijke
Molecular Cell Biology
Leiden University Medical Center, Leiden, The Netherlands

Carsten Peterson¹ ²
Computational Biology & Biological Physics
Lund University, Lund, Sweden

¹These authors have contributed equally.
²Carsten Peterson. Address: Computational Biology & Biological Physics, Department of Theoretical Physics, Lund University, Sölvegatan 14A, SE-223 62 Lund, Sweden, Tel.: +46 46 2229002, Fax: +46 46 2229686
Abstract

We present a rate equation model for the TGF-β pathway in endothelial cells together with novel measurements. This pathway plays a prominent role in inter- and intracellular communication and subversion can lead to cancer, fibrosis vascular disorders and immune diseases. The model successfully describes the kinetics of experimental data and also correctly predicts the behavior in experiments where the system is perturbed.

A novel method in this context, simulated tempering, is used to fit the model parameters to the data. It provides an ensemble of high quality solutions, which are analyzed with clustering methods and display a hierarchical structure highlighting distinct parameter subspaces with biological interpretations.

This analysis discriminates between different biological mechanisms to achieve a transient signal from a sustained TGF-β input, where one mechanism is to use a negative feedback to turn the signal off.

Further analysis in terms of parameter sensitivity reveals that this negative feedback loop in TGF-β signaling renders the system global robustness. This sheds light upon the role of the Smad7 protein in this system.

Key words: Signal transduction networks, systems biology, dynamical systems, robustness
1 Introduction

General Considerations

Mathematical modeling of signal transduction networks using rate equations is increasingly attracting attention as a powerful tool (see e.g. (1–5)). It is used to simulate the kinetics of large signaling networks, where one cannot only rely on biological intuition. In such studies, the aim is to identify and shed light on the role of key components and modules. Furthermore, such approaches allow for predicting quantities not yet measured.

Rate equation modeling involves three major steps: (1) Specify the components and their interactions and set up the system of equations. (2) Find values for the kinetic parameters from experimental estimates or by fitting the model to experimental kinetic data. (3) Analyze the behavior of the model for extracted parameter values.

Step 2 often presents the main limitation for a pathway modeling approach. The systems tend to have many parameters where only a few (if any) have values that represent reliable estimates from experiments. Also, the experimental kinetic data is typically not sufficient to constrain the parameter values to a single optimal solution, and multiple parameter sets can explain the available data. We address this problem by consistently looking at ensembles of parameter sets, where these sets subsequently are clustered with unsupervised methods, providing explanatory insights into the data and related biological interpretations.

A novel tool in this context is developed to deal with the optimization of parameters, Simulated Tempering (ST), which has previously been used
Kinetics and robustness of the TGF-β pathway

...to map out thermodynamical properties of protein folding models (6, 7). As with any other Monte Carlo method, ST naturally provides ensembles of solutions rather than single ones, subject to analysis by standard clustering techniques.

In this paper, we apply the rate equation methodology to the Transforming Growth Factor β (TGF-β) pathway in endothelial cells. The members of the TGF-β superfamily are responsible for many different biological functions, including proliferation, differentiation, apoptosis, embryonic development and wound healing. Perturbations in the TGF-β pathway has been detected in several human diseases, most notably in many forms of cancer and also in fibrotic diseases of the liver, the kidney and the lung (8). This pathway is not too large for modeling as there are sufficient number of measurements available to infer the value of the parameters available. Neither is it small enough to use visual inspection or a simple ON/OFF language as means to draw conclusions about its dynamics and function. We compare the models both to existing data (9, 10) and to novel measurements first presented here. The experiments consist of kinetic (time-course) measurements following TGF-β stimulation under different conditions; untreated cells and three cases, where different components of the pathway have been perturbed. Two of the experiments are used to fit the model parameters and the other two are left as "blind test" experiments. In addition, we predict the response of the system when varying the ligand dosage. Thus we develop a predictive model that is tested against existing data. Furthermore, we make testable predictions for further experiments. We also identify among other things a feedback loop (Smad7) as important for explaining all data sets used and
Kinetics and robustness of the TGF-β pathway

for the stability of the model.

To our knowledge, this is the first time the TGF-β pathway including regulatory aspects is approached with dynamical models. Recently, Vilar et al. (5) presented a detailed receptor model for TGF-β signaling, and we will discuss how this model relates to our simplified receptor description.

The TGF-β pathway in endothelial cells

The TGF-β signaling pathway in endothelial cells (see Fig. 1 for a simplified layout) is triggered by the TGF-β protein, which acts as a ligand, by binding to and activating a heteromeric complex of type I and type II serine/threonine kinase receptors. The type I receptor acts downstream of the type II receptor and the signal is propagated inside the cell as the activated receptor complex is internalized and binds to and phosphorylates a protein of the Smad family, called receptor-regulated Smads or R-Smads (11–13). The R-Smads include Smad1, Smad2, Smad3, Smad5 and Smad8. The phosphorylated R-Smads can form complexes with Smad4, also referred to as Co-Smad (11, 12). These complexes move into the nucleus where they regulate the transcription of target genes. There is also an inhibitory effect generated by the inhibitory-Smads (I-Smads), Smad6 and Smad7 (11, 12). The I-Smads negatively regulate the TGF-β signaling pathway by binding to the receptors and compete with R-Smads for receptor interaction, by recruiting ubiquitin ligase to activated receptor complexes and thereby target the receptor for proteasomal degradation or by recruiting phosphatases that inactivate the type I receptor by dephosphorylation (12–14).

In most cell types, TGF-β signaling is mediated via the type I receptor
activin receptor-like kinase 5 (ALK5). In endothelial cells it is also mediated by the similar ALK1 kinase. Endothelial cells make up the endothelium, a single layer of flattened cells, which are responsible for the formation connective tissues such as blood cells, blood vessels, etc. Since neovascularization plays a rate limiting step in cancer progression, research has frequently been focused on endothelial cells (15).

The two receptor proteins ALK1 and ALK5 give rise to two distinct pathways, which in turn induce opposite cellular functions. The TGF-\(\beta\)/ALK5 pathway induces the phosphorylation of Smad2 and Smad3 whereas the TGF-\(\beta\)/ALK1 pathway is responsible for the phosphorylation of Smad1 and Smad5. Moreover, ALK5 inhibits migration and proliferation while ALK1 stimulates these processes (9).

The phosphorylated R-Smads also display different behaviors in endothelial cells. It has been shown in (10) that the negative regulation of Smad1/5 is dependent on some newly synthesized protein and that Smad7 is induced by TGF-\(\beta\)/ALK1 signaling but unaffected by the TGF-\(\beta\)/ALK5 signaling. An interpretation of this would be that in endothelial cells TGF-\(\beta\) induced activated Smad1/5 together with Smad4 activates the production of Smad7. The effect of Smad7 on the two pathways is also different. It has been shown to inactivate the ligand-bound ALK1 receptor. It can target the activated receptor for an ubiquitin ligase dependent degradation (14, 16). Smad7 can also recruit a phosphatase to the activated ALK1 receptor and thus inhibiting further phosphorylation of Smad1/5 (10). It has been shown that only high levels of Smad7 have an inhibitory effect on phosphorylated Smad2 (10). This leads to the conclusion that Smad7 negatively regulates the phosphory-
lation of both Smad1/5 and Smad2 but the strength of the latter interaction is much weaker.

The putative TGF-β-induced negative feedback from Smad7 is an interesting aspect of the pathway. What is its purpose? If it is merely to shut off the ALK1 pathway, could this not be controlled by simpler means; for example in form of creation and degradation? These are two main questions investigated in our computational analysis of the pathway.

2 Materials and Methods

Use of Experimental Data

Relative concentration levels for phosphorylated Smad1 (PSmad1) and phosphorylated Smad2 (PSmad2) are estimated from Western Blot analysis. The time course data sets are from five different experiments following TGF-β stimulation, and both novel and existing measurements are used. The data sets consist of:

I. A non-perturbed experiment (control), where the cells are only stimulated with TGF-β. This new experiment is described below.

II. The cells are treated with the protein synthesis inhibitor cyclohexamide, which is modeled by completely blocking all protein production (10).

III. The cells are treated with the proteasome inhibitor MG-132, which is modeled by removing the proteasomal degradation of all proteins (10).
IV. The cells are treated with the phosphatase inhibitor orthovanadate, which is modeled by removing the phosphatases from the model (10).

V. An additional non-perturbed experiment, where the dose-response of phosphorylated Smad1 and Smad2 is measured by varying the amount of TGF-β (9).

In experiment I-IV the concentrations are measured at times 0, 45, 90, 120, 180 and 240 minutes after TGF-β addition. In order to investigate the early dynamics of the pathway we have also performed additional measurements of experiment I at times 0, 5, 15, 30, 45, 60, 120. The dose-responses, experiment V, are measured after 45 minutes only. The doses in this experiment varied from 0 to 5 ng/ml in 6 steps.

There are many possible ways to fit the model to experimental data, many of which display non-biological behavior. In order to reduce the number of possible solutions, we fit to more than one set of experimental data. For detailed studies, we use experiments I, II, and V for this calibration, whereas the others are used as “blind test” experiments. In this way the predictive power of our approach is tested. We also permute the experiments used for calibration to investigate the effects of such alterations.

Details of new measurements

**Kinetics of TGF-β3 induced Smad2 phosphorylation versus TGF-β3 induced Smad1/5 phosphorylation.** Mouse Embryonic Endothelial Cells (MEEC) were stimulated with 1 ng/ml TGF-β3 for different time points before lysis, fractionated by 6% SDS-PAGE and blotted. As a positive
control, 293 cell lysate transfected with either Smad2/constitutively active ALK5 (PS2) or Smad1/constitutively active ALK1 (PS1) were used. The filters were incubated with phospho-Smad2 or phospho-Smad1 antibodies, detection was performed by enhanced chemoluminescence (ECL).

**Ligands and cells and Western blot analysis.** Recombinant TGF-β3 were obtained from K. Iwata (OSI Pharmaceuticals, Melville, NY). All assays were performed with both ligands with essentially the same results. Recombinant BMP6 was a gift from Dr K. Sampath (Curis, Inc. Cambridge, MA). MEECs were cultured and Western blot analysis was performed as described in (9) and shown in Fig. 4C below.

**The Model**

Our aim is to develop a model versatile enough to be able to explain current data for the TGF-β pathway in endothelial cells and where the perturbation experiments described above can be naturally implemented. At the same time, each individual reaction step should be described as simple as possible in order to keep the number of parameters low. To this end we model the TGF-β pathway as described in Table 1 (cf. Fig. 1). All reactions are assumed to be reversible and constant production and degradation of all the non-phosphorylated proteins are allowed for.

**Receptor dynamics.** We only include the Type I receptors explicitly which are activated by TGF-β, and do not include receptor internalization and recycling (Fig. 2). This simplistic description of the receptor dynamics can be compared with a recently introduced rather detailed model for the TGF-β receptors, which takes into account phenomena such as receptor
recycling and trafficking (5). This detailed model is capable of describing different kinds of receptor responses to extracellular ligand concentrations depending on the situation at hand. We demonstrate that, regardless of the simplifications, our receptor model behaves strikingly similar to the more complicated of Vilar et al., at least as long as only one ligand of the TGF-β superfamily is present (see Supporting Text for details). An explanation for this similarity is that although our simplistic receptor model has much fewer parameters it does include variants of the parameters pinpointed as the most important ones by Vilar et al., which are determining the ratio of degradation of the unbound compared to the activated receptor. Also, we do not account for spatial factors for receptor membrane localization, which has recently been shown to improve receptor models in some situations (17).

**Phosphorylation and complex formation.** The activated receptors catalyze the phosphorylation of the R-Smads (Smad1, Smad2), which is described by a Michaelis-Menten formalism. PSmad1 and PSmad2 can form complexes with Smad4, and the complex including PSmad1 can move into the nucleus and induce Smad7 production. We assume a constant volume difference between the cytoplasm and nucleus, which can be integrated into model parameters and nucleus concentration unit and hence the volumes are not explicitly introduced in the model.

**Feedback inhibition.** As described above, Smad7 has an inhibitory effect on the signal. This is modeled by recruitment of the phosphatase $P_A$ ($P_B$) to the activated ALK1 (ALK5), which leads to an inactivation of the receptor. Since an ubiquitin ligase dependent degradation of the activated receptor leads to a similar inactivation behavior we do not account for this
process explicitly in the model.

**Formalism.** The reactions in Table 1 are implemented with standard rate equations using deterministic ordinary differential equations (Table 2). This assumes an ample amount of molecules involved and not to rare events. These conditions are very likely satisfied in the TGF-β case. For all reactions we use mass action or Michaelis-Menten enzyme kinetics. The complete set of equations are given in Table 2. As an example the equation for Smad1 concentration is given by

\[
\frac{d[\text{Smad1}]}{dt} = p_2 - p_2p_3[\text{Smad1}] + p_{17}[\text{PSmad1}] - \frac{p_{15}[\text{Smad1}][\text{TA1}]}{p_{16} + [\text{Smad1}]},
\]

which can be deduced from rows i and l in Table 1 (cf. Fig. 1). [X] denotes the concentration of molecule X and the p’s are kinetic parameters. We have chosen to use the parameterization \(r(1 - \frac{1}{r}[X])\) for the production and degradation terms where \(r\) and \(l\) correspond to the production rate and the equilibrium level for the production/degradation terms respectively. These equilibrium levels are also used as initial concentrations in the simulations.

**Computational Procedures**

We use a general computational procedure which can be divided into calibration and analysis (see Fig. 3). In the calibration part we extract parameter value sets that describe experimental data well, which results in an ensemble of solutions. The calibration consists of two parts: (1) Optimization, where the parameters are adjusted for the model to fit the experimental data and (2) Filtering, where good solutions from the optimization procedure are
Kinetics and robustness of the TGF-β pathway 11

evaluated against other experimental knowledge. These procedures require multiple simulations of the model, where the result of the numerical integration of the ordinary differential equations (ODEs) is compared with the experimental data. In the analysis part we investigate the behavior of the solutions following from the calibration step. As a first step, the solutions are grouped by clustering. The resulting subgroups are further evaluated by examining the group-averaged behavior. In a validation step the solution behavior is compared with “blind test” experiments, where the predictive power of the solutions is investigated. Also, we analyze how robust the solutions are with respect to perturbation of the parameters.

**Solving the system of ordinary differential equations.** The efficiency of the differential equation solver is extremely important since this is where most computational time is spent, in particular since the equations are often stiff. We use a procedure that adaptively switches between two methods to minimize the computational load: (1) Fifth order Runge Kutta method, where the step size is varied in order to keep the local truncation error constant, using an embedded fourth order method in order to estimate the truncation error and (2) the Rosenbrock method which is a an implicit method that uses the same kind of step size control as (1), but is more efficient in the regions of parameter space where the ODEs become stiff. Both methods are described in (18) and initial parameter values and other details in this procedure can be found in the Appendix.

**Calibration.** In the optimization procedure we estimate the parameters of the model by fitting to experimental data. After each solution to the ODEs in the iterative process, the $K$ parameters $\mathbf{p} = (p_0, \ldots, p_{K-1})$ are
Kinetics and robustness of the TGF-β pathway

adjusted such that the model should more accurately describe the experimental data. The latter consist of \(N\) discrete time points \(t_1, t_2, \ldots, t_N\) for each experiment. As error measure, the quadratic difference is used,

\[
R(p) = \frac{1}{N} \frac{1}{M} \sum_{i=1}^{t_N} \sum_{i=1}^{M} (x_i(t) - \tilde{x}_i(t))^2,
\]

where \(x_i(t, p)\) and \(\tilde{x}_i(t)\) denote model points and experimental points respectively and the index \(i\) denotes the different molecules (\(M\) in total). We use two experiments in the optimization procedure, and the sum of the two \(R\) values is used as error measure. In order to find good approximate solutions to global minima for Eq. 2, one can for example use Monte Carlo methods like Simulated Annealing (SA) (19). Here, we employ a related but more powerful method, Simulated Tempering (ST) (6, 7), where the fictitious temperature is a dynamic variable, and the system is always kept at equilibrium for the different temperatures. Solutions are obtained by "quenching" from the lowest temperature to \(T = 0\) corresponding to a local search. The underlying idea is to scan sizable parts of the solution space at different high temperatures and regularly visit low temperature solutions. In a sense, this optimization method corresponds to SA with multiple random starts and it yields ensembles of solutions rather than single ones. The details of the ST implementation are found in the Appendix.

To further restrict the behavior of solutions included in the analysis, we select solutions from the optimization step to correctly describe the dosage experiment V. We run the model for different dosages of TGF-β and calculate a measure similar to \(R\) (see Appendix for details). Finally, a small
Kinetics and robustness of the TGF-β pathway

subset of these solutions are removed based on an “over-fitted” behavior (20).

Solution properties. In order to investigate properties and interior structures of the solution space we use three different methods: (1) Hierarchical clustering, (2) K-means clustering, and (3) Principal Component Analysis (PCA). Before this analysis, the data is pre-processed to obtain a distribution for each parameter with zero mean and standard deviation one (for details on the implementation see the Appendix).

Robustness. A common method used to analyze the robustness of a system is to use the derivatives of the molecule concentrations, $x_i(t, p)$, with respect to the different parameters, $p$, as a direct measurement of the sensitivity of the system (21). We define a sensitivity vector according to

$$s_j \equiv \frac{p_j}{M} \sum_{i=1}^{M} \left( \sum_{k=1}^{N} \left[ \frac{1}{x_i(t_k)} \frac{\partial x_i(t_k)}{\partial p_j} \right] \right)^2 \frac{1}{2}, \quad (3)$$

where the derivative is approximated by a simple finite-difference approximation, using 1% parameter variations.

3 Results

Calibration. First we generate an ensemble of solutions from fitting to the control (I) and cyclohexamide (II) experiments. Good solutions are selected with the criteria $R < 0.01$ yielding approximately 200 solutions. As can be seen from Fig. 4, these solutions fit both experiments well. Hence the parameterization form is appropriate and the optimization method efficient.
Next we select for those solutions that at the same time successfully describe the saturated behavior at different TGF-β dosages (experiment V). An ensemble of 38 solutions pass this filtering step (see Fig. 5), from which four are removed based on an over-fitting criteria (20). The remaining 34 solutions are used for further investigations.

**Solution properties.** Individual parameter values varies considerably in the calibration solution set; most with ranges of several orders of magnitude. To analyze the homogeneity of the solutions we cluster the ensemble of parameter sets using different clustering algorithms and distance measures. The result for hierarchical clustering with a Pearson correlation distance measure is shown in Fig. 6A, where two main groups can be identified. Also K-means clustering with K=2 results in a similar grouping. Fig. 6B shows the K-means result projected onto the two main directions from a principal component analysis. As will be shown in a more detailed analysis, the two groups of solutions define two very distinct biological interpretations of how the PSmad1 signal is made transient in the case of a sustained TGF-β input: All the group 2 solutions use the putative Smad7 feedback loop, while the solutions of group 1 do not. This division of the solutions is very robust to a variety of settings in the clustering algorithms. Occasionally, a small set of the solutions emerge as outliers, and also two of the solutions end up in different clusters depending on method (cf. Fig. 6A and 6B). Although our analysis does not depend upon the assignment of these two solutions, we choose not to include them in the further analysis. The parameter values for these 32 solutions are provided as a Supporting File.

We also performed clustering on a subset of the solutions that do not
Kinetics and robustness of the TGF-β pathway

correctly describe the dose response experiment, but still satisfy $R < 0.01$. In this case we get equivalent results, with two distinct groups with the same difference in biologically interpretable behavior with one group using the Smad7 feedback loop, whereas the other group do not (data not shown).

**Prediction.** The solutions that were clustered were chosen to accurately predict the dosage experiment (Fig. 5). To further analyze the predictive power of the two defined ensembles of solutions we have performed two "blind test" experiments: Cells treated with the proteasome inhibitor MG-132 (III) and phosphatase inhibitor orthovanadate (IV) respectively. In Fig. 7, the model predictions from group 1 and group 2 are shown and compared with experiments, again for levels of PSmad1 and PSmad2. As can be seen, the PSmad2 levels are not affected significantly in either of the perturbed systems as compared to the control experiment (Fig. 4A). This behavior is accurately predicted by both groups of solutions. In the MG-132 experiment (see Fig. 7A), the PSmad1 signal still appears transient although the peak is broadened in time. Both groups of solutions predict a transient PSmad1 signal very similar to the behavior of the control experiment in this case. This lack of broadening of the peak for all solutions are discussed in more detail below, where we do optimization on control and MG-132.

It is in the PSmad1 behavior in the Orthovanadate experiment (see Fig. 7B) where the predictions from two groups distinctly differ. In this case group 1 predicts a transient PSmad1 signal very similar to the behavior in the control experiment, whereas group 2 predicts a more sustained signal in closer agreement with the experimental values. This experiment (and model perturbation) mainly affects the feedback from Smad7 by dis-
abling the phosphatase to inactivate the activated ALK1 receptor, and the behavior of group 1 in this case indicates that these solutions do not use the feedback loop.

It should be noted that these experiments are quite crude and may affect the cells in ways not feasible to include in our model, which is restricted to the molecules directly involved in the TGF-β pathway. A much more direct experiment for model prediction would be to perturb a single specific molecule included in the model, e.g. silencing Smad7 by a siRNA knockdown. The predicted PSmad1 and PSmad2 behaviors for the two groups when Smad7 is silenced are shown in Fig. 8. This is particularly interesting since the two solution groups exhibit very different behaviors. Again, the unchanged PSmad1 behavior of group 1 shows that these solutions do not need the Smad7 feedback to achieve a transient signal. The prediction for the feedback model is dependent on the assumption that Smad7 is the I-Smad active in endothelial cells which is based on experiments. Smad6 could potentially also be active although there is no data for Smad6 behavior in endothelial cells. In other cell types, Smad6 has been shown to be more moderately and transiently induced by TGF-β compared to Smad7 (22, 23). A fair assumption would be that if Smad6 is induced in endothelial cells its behavior would resemble the Smad7 behavior, which would lead to similar behavior for a model including Smad6 in all previous experiments but not for the Smad7 knockdown experiment. Instead the effect of Smad7 knockdown would be less pronounced in such a feedback model.

**Robustness.** To further illuminate differences between the two groups of solutions, we computed the sensitivity as defined in Eq. 3. In Fig. 9 the
sensitivity of the two groups are shown, where the summed derivatives of PSmad1 and PSmad2 with respect to the parameters for experiments I and II are displayed. It is clear that the group using the Smad7 feedback loop (group 2) is more robust than the other group. A Wilcoxon two sample test on the measure $\sum_j s_j$ for the solutions in the two groups gives a p-value less than $10^{-6}$. The largest difference is found in the parameters governing the production and degradation of Smad1 and Smad4 (parameters $p_2 - p_5$). This indicates that group 1 uses Smad1 and Smad4 production and degradation in order to achieve the transient PSmad1 signal instead of using the negative feedback of Smad7. It is indeed very interesting that the transient signal can be achieved by a pathway with fewer molecular players, but it appears that the drawback for the cells would be that the levels and production/degradation rates for the Smad1 and Smad4 need to be tightly regulated to achieve a robust signal behavior. In contrast to this, the group that uses the Smad7 feedback shows a low sensitivity in respect to Smad4 levels ($p_4, p_5$), and more or less no sensitivity at all to Smad1 levels ($p_2, p_3$). This latter fact, and the lack of sensitivity towards changes of the Michaelis-Menten constant in the phosphorylation step ($p_{16}$) indicate that the Smad1 levels are saturated. A more detailed look at the parameter values and Smad1 levels reveals that all solutions in group 2 indeed have saturated levels of Smad1 (data not shown), which hence can be regarded as a prediction of the model using Smad7 feedback.

Group 1 is insensitive to perturbations in all parameters directly included in the Smad7 feedback pathway ($p_{10} - p_{12}, p_{27}, p_{28}, p_{31}, p_{32}$), which agrees with the conclusion that the feedback is not used by these solutions.
Group 2, on the other hand, shows some sensitivity in these parameters except for the parameters included in the Smad7 feedback on the activated ALK5 receptor ($p_{31}, p_{32}$). Neither of these solution ensembles make use of a Smad7 feedback for regulating PSmad2 levels, and this part of the network could have been left out of the model, at least for explaining the current experiments (cf. (10)).

The most sensitive parameters in group 2 are $p_{1}, p_{9}, p_{15}, p_{17}, p_{22}$ and $p_{24}$, and group 1 is about equally sensitive to these parameters. These parameters govern the initial ALK1 and ALK5 levels ($p_{1}, p_{9}$), as well as the rates of phosphorylation and dephosphorylation of Smad1 ($p_{15}, p_{17}$) and Smad2 ($p_{22}, p_{24}$). The early PSmad1 and PSmad2 kinetics and also (at least partly) the entire PSmad signals are dependent on these parameters. Hence, it is expected that the fitting to our kinetic PSmad1 and PSmad2 data is sensitive to these parameters. A final note is that although the ALK1 and ALK5 levels are important, the production and degradation rates are not ($p_{0}, p_{9}$). A more detailed look at the parameter levels show that these rates are low (data not shown), and it appears that it is the initial values that are important for the model to explain data.

**Permuting the experiments for the calibration.** To further analyze the model behavior we also permuted the experiments used for calibration. We used combinations including the control experiment in the calibration part since this is the only experiment where all the parameters are present. Also here we applied the dose experiment as a filtering step after optimization. The two additional calibration sets used were optimization on control (I) and MG-132 (III), and on control (I) and orthovanadate (IV) experi-
ments. The new parameter sets are presented in a PCA-plot in Fig. 10 together with the previously defined parameter sets.

When optimization is performed on control and orthovanadate, the extracted solutions behave very similar to the ones extracted from optimization on control and cyclohexamide (see Supporting Text Fig. S4). All these solutions use the Smad7 feedback in the process of truncating the PSmad1 signal, which is expected since the optimization includes the orthovanadate experiment, which mainly affects the feedback. Also, the robustness analysis on this new data set shows a very similar pattern as for the previously defined Group 2 (data not shown).

In the case of optimizing against the control and MG-132, the optimization procedure works less efficient. Among the solutions provided by the algorithm only very few resulted in $R < 0.01$ and among those none passed the filtering step against the dose experiment (see Appendix for details). The parameter sets from this case provided in Fig. 10 are solutions with $R < 0.015$ which pass the dose experiment filter. These solutions show an average behavior for the PSmad1 lying in between the experimental curves for control and MG-132, and with very small change in behavior when protein degradation is removed (see Supporting Text Fig. S4). None of the parameter sets use the Smad7 feedback and hence provide a poor prediction of the orthovanadate experiment, while the predictive power is small for the cyclohexamide experiment since the behavior is very spread out. An interesting note is that this apparent conflict for explaining the MG-132 together with the other experiments can be used to direct improvements for the model. This is illustrated by a slight adjustment of the model perturbation
for the MG-132 experiment where a decreased inactivation of the activated receptors is included (simulating reduced ubiquitin-dependent degradation), which leads to an improved behavior (see Supporting Text Fig. S5).

4 Conclusions and Outlook

We have developed a mathematical model for the TGF-β pathway in endothelial cells and introduced novel computational procedures for finding and analyzing robust models. This system was chosen given its paramount importance in diseases like cancer and in developmental processes, even though the information about concentrations, reaction rates and other parameters is scarce. To cope with the latter, we generate an ensemble of solutions rather than a single one when fitting to the data. This also means that we are less sensitive to noise and, as it turned out, we are able to identify different solution categories with associated biological interpretations. We use different kinetic data sets by varying conditions including knock-downs. Some of the data sets already exist and others are newly generated and are presented here for the first time. Having access to kinetic data under different conditions enables us to fit models to a subset of these and use the remaining sets for "blind test" evaluations. Our results can be summarized as follows:

- With efficient ODE solvers and a powerful optimization method, Simulated Tempering, good solutions are found to the calibration sets.

- The calibrated solutions are found to well reproduce "blind test" experiments including those, where the external dosage is varied.
The resulting solutions are analyzed with unsupervised clustering methods. Two clusters emerge, one where the Smad7 feedback loop is employed and one where this is not the case. The group using the Smad7 feedback is better at predicting the “blind test” experiments.

The robustness is investigated with a gradient method. It is found that the solutions corresponding to the cluster using the Smad7 feedback loop are less sensitive to parameter perturbations, indicating that a role for this loop is to provide robustness to the system.

Together, the two preceding items, strongly favours a model that includes the Smad7 feedback loop.

Permutation of the experiments used for optimization, resulted in similar solution sets, but also highlighted the MG-132 experiment as somewhat conflicting for the model to solve. This can be used to direct improvements of the model, which is indicated by simulations adjusting the interpretation of the MG-132 experiment.

In our robustness analysis we have investigated how the dynamical levels of different PSmads change for different parameter perturbations. The PSmads represent the signal through the pathway, but maybe a more biologically relevant measure is the robustness in cell response. Hence, in the future one should augment the PSmad concentration measurements with downstream gene expression data and perform an integrated analysis. In this context one should also include the effects from cross-talk with ”neighboring” pathways that are part of the TGF-β family.
Very recently, a detailed model for receptor dynamics was introduced in the context of the TGF-β pathway (5). It does not target endothelial cells specifically, but presents a detailed study of receptor dynamics including internalization and a specific inactivation of the ligand-bound receptor complex by degradation. This model is sufficient to explain a transient signal for PSmad2 after sustained TGF-β stimulation. To relate this to our more simplistic receptor model, not explicitly including receptor recycling, we showed that our receptor model has as versatile activation pattern when a single ligand is presented to the receptor. The behavior of PSmad1 in endothelial cells when treated with cyclohexamide is to extend the signal, while the same treatment in HaCaT cells has shown to shorten the PSmad2 signal (24). While the detailed receptor model predicts a shortened activation at cyclohexamide treatment (see Supporting Text Fig. S1) in full agreement with the PSmad2 data, our full pathway model can indeed explain the PSmad1 behavior in cyclohexamide treated endothelial cells.

From the behavior of our different solution groups, we argue for a model where there exists a feedback from TGF-β induced Smad7 to repress the PSmad1 activation. This is based on indications from several experiments, which are all reproduced by the feedback model. Needless to say, a more distinct test of this model would be to perform a dedicated knockdown experiments for Smad7, which is currently in progress in siRNA experiments targeting Smad7. In this context, also the importance of Smad6 in endothelial cells needs to be investigated.

Our approach is not restricted to systems where all parameter values can be experimentally estimated. Rather, it allows for several solutions to solve
a problem, and can account for similarities in behavior of highly conserved modules such as the TGF-β pathway, although quantitative details differ.

In this study we are confined to experimental data which has not been calibrated to units of concentration. This lack of knowledge propagates to our parameters. Also, the measurements are restricted to a few components, and we have therefore chosen a simplistic description of some of the reactions. Hence, we have focused on relevant biological behavior of the measured molecules for different conditions and not attempted to evaluate parameter values with respect to biologically reasonable ones, which would have been dependent on further assumptions. Additional experiments, which provide quantitative estimates of parameters and concentration levels, are important and will constrain the solution space for the models. On the other hand, we demonstrate that the models, can pinpoint experiments that will provide maximal information given the current knowledge, and the combination of experiments and modeling provides an effective methodology for an increased understanding of highly complex biological networks.
Appendix

Experimental Data. All the experimental data originate from Western Blot Analysis, where we measure the average intensity in a square on the inverted blot-images and use these intensities as a relative measure of concentration. As it turns out, the size of the square has only a marginal effect on the estimated concentration levels. The concentrations are normalized with the actin level measured in the cell, which is fairly constant throughout the time series. Finally, the concentrations are normalized to give a maximum value of one for both PSmad1 and PSmad2.

Solving the systems of ODEs. In Table 2 we show the system of ODEs used in our calculations, in which the following assumptions are made in the calibration process:

1. The TGF-β level is constant throughout the time series.

2. At $t = 0$ we have

   $$
   P_1(0) = T_1(0) = P_2(0) = P_{14}(0) = P_{24}(0)
   = T_1(0) = T_5(0) = T_{1P}(0) = T_{5P}(0) = 0 .
   $$

3. The system is in equilibrium at $t = 0$ (for zero TGF-β level), which with Eq. A1 leads to

   $$
   A_1(0) = 1/p_1, \quad S_1(0) = 1/p_3, \quad S_4(0) = 1/p_5,
   $$

   $$
   S_2(0) = 1/p_7, \quad A_5(0) = 1/p_9 .
   $$
The ODEs are solved using mainly the fifth order Runge-Kutta method, but in stiff regions of parameter space we switch to the Rosenbrock method using an adaptive procedure. For details on the ODE solvers see (18).

**Parameter estimation.** For generating ensembles of solutions we use Simulated Tempering, where configurations are generated for different fictitious temperatures $T_j$ and the system is allowed to move between the different $T_j$. In other words, at a given Monte Carlo step one updates the system by swapping configurations of the systems, or alternatively trading two temperatures. The method amounts to simulating the joint probability distribution

\[ P(p, j) \propto \exp(-g_j - R(p)/T_j) , \tag{A3} \]

where the "energy" $R(p)$ is the error measure of Eq. 2 with its system parameters $p = (p_1, \ldots, p_K)$. The algorithm parameters $g_j$ govern the weights $p_j$ of the different temperatures, $T_j$. The latter are chosen according to

\[ T_j = T_{\text{min}} \left( T_{\text{max}}/T_{\text{min}} \right)^{(j-1)/(J-1)} , \quad j = 1, 2, \ldots, J , \tag{A4} \]

where we used $J = 20$, $T_1 = T_{\text{min}} = 0.0025$ and $T_{20} = T_{\text{max}} = 0.005$. We want to spend roughly the same amount of time on each of the temperatures, and thus have to choose our $g_j$'s accordingly, i.e. we want to choose our $g_j$'s such that the weights, $p_j$, are equal for all $j$. This is done through trial simulations in a two-step process. First we calculate rough estimates of the average "energy" at each temperature, $\langle R \rangle_j$ and put $g_{20} = 0$ and $g_{j-1} = g_j - \langle R \rangle_j (1/T_k - 1/T_k)$. In the next step we perform longer simulations in order to obtain good estimates of the weights $p_j$, the uniform
distribution is then obtained by replacing \( g_j \) with \( g_j + \ln p_j \) (7).

The parameters are updated one at a time with \( p_i \rightarrow r \cdot p_i \), where \( r \) is a multiplicative factor \( (r = 1.1 \text{ is used}) \) and in 50% of the cases we set \( r \rightarrow 1/r \). At \( T = T_{\text{min}} \), \( r \) is allowed to vary freely in the range \( r \in [1 : 2] \) individually for each parameter, in order to keep the acceptance ratio above 50%. Updates are accepted according to Eq. A3. For each \( K \) number of attempted parameter updates, \( K \) being the number of parameters, we attempt one update to an adjacent temperature \( T_{j \pm 1} \) with a probability also governed by Eq. A3.

The performance of the algorithm is displayed in the table below showing the number of simulations it takes on average to find a minimum (middle panel) and the percentage of these minima having \( R < 0.01 \) (right panel) for each of the three sample permutations. These results can be compared with for example (25) where different optimization algorithms including simulated annealing are compared. The poor performance on the control+MG-132 set is discussed in the text and in the Supporting Text.

<table>
<thead>
<tr>
<th>Sample</th>
<th>No.of simulations</th>
<th>( R &lt; 0.01 )</th>
</tr>
</thead>
<tbody>
<tr>
<td>control+cyclohexamide</td>
<td>38919 ± 5872</td>
<td>32.9%</td>
</tr>
<tr>
<td>control+orthovanadate</td>
<td>26783 ± 4707</td>
<td>25.6%</td>
</tr>
<tr>
<td>control+MG-132</td>
<td>33374 ± 3326</td>
<td>1.4%</td>
</tr>
</tbody>
</table>

**Calibration.** In the first step we merely select for solutions \( \mathbf{p} \) satisfying \( R(\mathbf{p}) < 0.01 \). In the second step we also require the solutions to display the saturating behavior observed in experiment V. This is achieved by only
considering solutions $p^*$ satisfying

$$
\frac{1}{N} \frac{1}{M} \sum_{C=2.5}^{5.0} \sum_{t=1}^{t_N} \sum_{i=1}^{M} \left( x_i^{(C)}(t, p^*) - x_i^{(1)}(t, p^*) \right)^2 < \epsilon,
$$

(A5)

where $x_i^{(C)}(t, p^*)$ denotes the concentration of molecule $i$ at time $t$ given the parameters $p^*$ and an initial concentration of TGF-$\beta$ of $C$ ng/ml. For the cut-off value $\epsilon$ we found $\epsilon = 0.05$ to be appropriate.

**Implementation** The calibration framework as well as the robustness analysis are implemented in C++. For the two clustering methods, K-means and hierarchical clustering, and for the PCA, we used the MATLAB implementations corresponding to the MATLAB functions `dendrogram`, `kmeans` and `princomp` respectively (26).

**Acknowledgments**

This work was in part supported by the Swedish Foundation for Strategic Research through a ”Senior Individual Grant” (CP), by the Knut and Alice Wallenberg Foundation through a Swegene Postdoc grant (HJ) and by the EC project ”Angiotargeting Integrated Project” # 504743 and the Dutch Cancer Society with grant NKI 2005-3371 (PtD). We also would like to thank Marie-Jose Goumans and Gudrun Valdimarsdottir for valuable discussions.

**References**


Computational modeling of the dynamics of the MAP kinase cascade
Kinetics and robustness of the TGF-β pathway


20. A small number (four) of the solutions display a “high-order” behavior in the simulations. Although these solutions do get a good $R$ value, the behavior do not fit the experiments well if the concentration levels are assumed to interpolate smoothly between the measurements. These solutions are removed by inspection, but could have been removed by e.g. using a criteria of not allowing for multiple peaks. If these solutions are included in the analysis they cluster with the group not using the feedback. The group behavior is not altered significantly, but the sensitivity and the variation in the predictions are slightly increased.

Kinetics and robustness of the TGF-β pathway


26. MATLAB. The MatWorks, Natick, CA.
Kinetics and robustness of the TGF-β pathway

Figure Legends

Fig. 1.
The TGF-β pathway in endothelial cells. The ligand, TGF-β, binds to the receptors ALK1 or ALK5, and induces phosphorylation of Smad1/5 and Smad2 respectively which in turn form complexes with Smad4. These complexes move into the nucleus where they control gene expression. Smad7 expression is induced during this process and negatively regulates the ALK1 pathway. (In the calculations we have also allowed for a negative regulation on the ALK5 pathway which is not shown here.)

Fig. 2.
Simplified receptor model. The ligand TGF-β binds to a type I receptor (ALK1 or ALK5) and forms an active complex that mediates the signal via the phosphorylation of R-Smads. The active receptors are inactivated by Smad7 which recruits phosphatases to the active receptors. We also allow for a constant production and degradation of the inactive receptors.

Fig. 3.
Flowchart of the calibration and validation process. Solutions are found in two steps; optimization followed by an independent test of the solutions against dose response tests. The solutions surviving these two steps are then clustered, which results in two distinct groups displaying different behavior. Group 1 does not use the Smad7 feedback loop whereas group 2 does. The numbers on the right-hand side show the number of solutions in the different
Kinetics and robustness of the TGF-β pathway

steps.

Fig. 4.

*Left panel of (A) and (B)*: Experimental data from Western Blot analysis for the control experiment (A) and the cyclohexamide experiment (B) (adapted from (10)). *(C)* Additional measurements of the control experiment in order to illuminate the early behavior of the pathway. *Middle panel of (A) and (B):* An average area intensity in the inverted image is used as a measure of relative concentration levels. These are given relative to the actin level measured in the cell, and normalized to a maximal value equal to one (see Appendix for details). *Right panel of (A) and (B):* Simulation results. Concentrations of PSmad1 and PSmad2 as functions of time for the control experiment (A) and cyclohexamide treated systems (B) (experiments I and II in Materials and Methods). The curves with error bars correspond to averages and standard deviations for the ensemble of model solutions resulting from fitting to the data (227 solutions in total).

Fig. 5.

Dose response model predictions of PSmad1 (A) and PSmad2 (B) concentrations respectively. Doses scaled to the one used for the experiments in Fig. 4. Also shown are the corresponding measurements taken after 45 minutes (adapted from (9)). The +, △ and the × symbols refer to the experimental data points after 45 minutes for 0.025, 1.0 and 5.0 ng/ml respectively. The time series show the corresponding predictions from the ensemble with standard deviations.
Fig. 6.

(A) Hierarchical clustering analysis of the solutions determined from experiments I and II (see Fig. 4) subject to the constraints that $R < 0.01$ and that the dose experiments in Fig. 5 are well predicted (see text). The left branch (group 1) corresponds to solutions where the Smad7 feedback loop is not used, while the right branch (group 2) uses the Smad7 feedback loop. (B) Results from PCA with the grayscale referring to the groups found in the K-means clustering. The group on the left is group 1 (gray) and the one on the right is group 2 (black). The crosses are the two cluster centers found by K-means clustering using a squared Euclidean metric. The arrows refer to the two solutions where the clustering algorithms disagree, these solutions have been left out in the further analysis.

Fig. 7.

(A) Data and model predictions of PSmad1 and PSmad2 concentration when the cells are treated with the proteasome inhibitor MG-132, which is modeled by removing the proteasomal degradation of all proteins (experiment III). The solutions used are those of group 1 and group 2 as defined by the clustering (see Fig. 6). (B) Data and model predictions of PSmad1 and PSmad2 concentrations when the cells are treated with the phosphatase inhibitor orthovanadate, which is modeled by removing the phosphatases (experiment IV), with the same grouping as in (A). The time series show the predictions from the two ensembles with standard deviations. All data are adapted from (10).
Fig. 8.

Predictions of PSmad1 and PSmad2 concentrations when silencing Smad7 using the solutions of group 1 and 2 respectively, as defined by the clustering (see Fig. 6). The time series shows the predictions from the two ensembles with standard deviations.

Fig. 9.

Sensitivity analysis using derivatives of the PSmad1 and PSmad2 concentration with respect to the different parameters of the model. The sensitivity measure (Eq. 3) is represented on the y-axis, where group 1 is above the x-axis (positive direction upwards) and group 2 is below the x-axis (positive direction downwards). Group 2, which uses the Smad7 feedback loop, is found to be more robust than group 1. The figure shows group averages with estimated errors.

Fig. 10.

PCA plot of solutions found when different experiments are used for optimization. The straight line separates the ones that are using the Smad7 feedback loop (right) from those that do not (left) (cf. Supporting Text Fig. S4). A total of 105 solutions have been used, where 32 solutions are from optimizing on the control (I) and the cyclohexamide (II) sets, 28 solutions are from optimizing on the control (I) and the MG-132 (III) sets and 45 solutions are from optimizing on the control (I) and the orthovanadate (IV) sets.
Kinetics and robustness of the TGF-β pathway

Figures

Figure 1:
Figure 2:
Kinetics and robustness of the TGF-β pathway

Figure 3:
Kinetics and robustness of the TGF-β pathway

Figure 4:
Kinetics and robustness of the TGF-β pathway

Figure 5:

A: Dose response of PSmad1

B: Dose response of PSmad2
Figure 6:
Figure 7:
Figure 8:
Kinetics and robustness of the TGF-β pathway

Figure 9:

Figure 10:
Kinetics and robustness of the TGF-β pathway

Table 1: The different reactions in the TGF-β pathway model, where $p_i$ ($i = 0, 1, \ldots, 32$) are the rate constants. Reactions with the symbol $\emptyset$ model production and degradation. In reactions (k), (l) and (m) Michaelis-Menten dynamics is used.
\[ \frac{dA_1}{dt} = p_0(1 - p_1 A_1) - p_{13} T_\beta A_1 + p_{14} T_1 \]
\[ \frac{dS_1}{dt} = p_2(1 - p_3 S_1) - \frac{p_{15} T_1 S_1}{p_{16} + S_1} + p_{17} P_1 \]
\[ \frac{dS_4}{dt} = p_4(1 - p_5 S_4) - p_{18} P_1 S_4 + p_{19} P_1 T + p_{25} P_2 S_4 + p_{26} P_24 \]
\[ \frac{dS_2}{dt} = p_6(1 - p_7 S_2) - \frac{p_{22} T_2 S_2}{p_{23} + S_2} + p_{24} P_2 \]
\[ \frac{dA_5}{dt} = p_8(1 - p_9 A_5) - p_{20} T_\beta A_5 + p_{21} T_5 \]
\[ \frac{dS_7}{dt} = \frac{p_{11} P_{A1}}{p_{12} + P_{A1}} - p_{10} S_7 \]
\[ \frac{dP_1}{dt} = \frac{p_{15} T_1 S_1}{p_{16} + S_1} - p_{17} P_1 - p_{18} P_1 S_4 + p_{19} P_1 T \]
\[ \frac{dP_{A1}}{dt} = p_{18} P_1 S_4 - p_{19} P_1 T - p_{29} P_1 A + p_{30} P_1 A N \]
\[ \frac{dP_{A1N}}{dt} = p_{29} P_1 A - p_{30} P_1 A N \]
\[ \frac{dP_2}{dt} = \frac{p_{22} T_2 S_2}{p_{23} + S_2} - p_{24} P_2 - p_{25} P_2 S_4 + p_{26} P_24 \]
\[ \frac{dP_{24}}{dt} = p_{25} P_2 S_4 - p_{26} P_24 \]
\[ \frac{dT_1}{dt} = p_{13} T_\beta A_1 - p_{14} T_1 - p_{27} S_7 P A T_1 + p_{28} T_1 P \]
\[ \frac{dT_5}{dt} = p_{20} T_\beta A_5 - p_{21} T_5 - p_{31} S_7 P B T_5 + p_{32} T_5 P \]
\[ \frac{dP_A}{dt} = -p_{27} S_7 P A T_1 + p_{28} T_1 P \]
\[ \frac{dP_B}{dt} = -p_{31} S_7 P B T_1 + p_{32} T_1 P \]
\[ \frac{dT_{1P}}{dt} = p_{27} S_7 P A T_1 - p_{28} T_1 P \]
\[ \frac{dT_{5P}}{dt} = p_{31} S_7 P B T_5 - p_{32} T_{5P} \]

Table 2: Model equations of the TGF-β pathway. The abbreviations used are; S_i = [Smad]_i, T_\beta = [TGFβ], A_1 = [ALK1], A_5 = [ALK5], P_1 = [PSmad1], P_2 = [PSmad2], T_1 = [TA1], T_5 = [TA5], T_{1P} = [TA1P], T_{5P} = [TA5P], P_A = [phosphatase A] (responsible for the inhibition of the ALK1 pathway) and P_B = [phosphatase B] (responsible for the inhibition of the ALK5 pathway).